Status:
RECRUITING
Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
Lead Sponsor:
YiHui Guan
Conditions:
Positron Emission Tomography
Pancreatic Neoplasms
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
In this study, we will investigate the diagnostic efficacy and safety of \[18F\]F-H3RESCA-3A12 and \[68Ga\]Ga-NOTA-3A12 in metastatic gastric and pancreatic cancers, and evaluate the sensitivity and s...
Eligibility Criteria
Inclusion
- (1) Age between 18 and 65 years old, gender is not limited. (2) Patients with gastric or pancreatic cancer confirmed by puncture or surgical pathology.
- (3) Written informed consent signed by the subject or his/her legal guardian or caregiver.
- (4) Willingness and ability to cooperate with all programs of this study.
Exclusion
- \- (1) Severe hepatic or renal insufficiency; (2) Targeted therapy before radiotherapy or PET/CT scan. (3)Renal function: serum creatinine less than or equal to the upper limit of the normal range;Liver function: bilirubin, AST(SGOT)/ALT(SGPT) less than or equal to the upper limit of the normal range.
- (4) History of serious surgery in the last month. (5) Those who have participated in other clinical trials during the same period.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06203613
Start Date
December 1 2023
End Date
December 1 2024
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PET Center, Huashan Hospital, Fudan University
Shanghai, China, 200235